Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Tissue Regenix ( (GB:TRX) ) has issued an announcement.
Tissue Regenix announced that it will release its interim results on 30 September 2025, with a live online presentation hosted by the CEO and Executive Chairman. This event is open to current and potential shareholders, indicating the company’s commitment to transparency and engagement with its stakeholders.
The most recent analyst rating on (GB:TRX) stock is a Hold with a £25.00 price target. To see the full list of analyst forecasts on Tissue Regenix stock, see the GB:TRX Stock Forecast page.
Spark’s Take on GB:TRX Stock
According to Spark, TipRanks’ AI Analyst, GB:TRX is a Neutral.
The overall stock score is primarily influenced by financial performance and technical analysis. While there are signs of operational improvement, persistent net losses and negative cash flows are significant concerns. The bearish technical indicators further weigh on the score, and the negative valuation metrics reflect market caution. The absence of earnings call data and corporate events limits additional insights.
To see Spark’s full report on GB:TRX stock, click here.
More about Tissue Regenix
Tissue Regenix is a leading company in the regenerative medical devices industry, specializing in decellularisation technology. Their products, which include acellular tissue scaffolds, are used in sports medicine, foot and ankle injuries, and wound care, addressing critical clinical needs.
Average Trading Volume: 76,947
Technical Sentiment Signal: Sell
Current Market Cap: £17.81M
Find detailed analytics on TRX stock on TipRanks’ Stock Analysis page.